USD 0.0
(0.0%)
Breakdown | 2022 | 2021 | 2020 | 2019 | 2006 | 2005 |
---|---|---|---|---|---|---|
Revenue | - | 6.87 Million | - | - | 4.52 Million | 3.76 Million |
Cost of Revenue | - | 4.18 Million | - | - | 1.59 Million | 1.16 Million |
Gross Profit | - | 2.69 Million | - | - | 2.92 Million | 2.59 Million |
Operating Expenses | - | 1.12 Million | 1000.00 | - | 7.89 Million | 6.42 Million |
Selling, General and Administrative Expenses | - | 1.12 Million | 1000.00 | - | 5.07 Million | 5.72 Million |
Research and Development Expenses | - | - | - | - | - | - |
Other Expenses | - | - | - | - | - | - |
Cost and Expenses | - | 5.3 Million | 1000.00 | - | 9.48 Million | 7.59 Million |
Operating Income | - | 1.57 Million | -1000.00 | - | -4.96 Million | -3.82 Million |
Interest Expense | - | 210.91 Thousand | - | - | - | 2.21 Million |
Income Tax Expense | - | -3.00 | -206.29 Thousand | - | 6.97 Million | -4703.00 |
Earnings before Tax | - | 1.22 Million | -1000.00 | - | -11.94 Million | -6.05 Million |
Net Income | - | 1.22 Million | -1000.00 | - | -11.94 Million | -6.04 Million |
Earnings Per Share Basic | - | 0.15 | -0.00 | - | - | -1260.70 |
Earnings Per Share Diluted | - | 0.15 | -0.00 | - | - | -1260.70 |
Weighted Average Shares Outstanding | 4.17 Million | 8.09 Million | 8.12 Million | 7.91 Million | - | 4796.00 |
Weighted Average Shares Outstanding (Diluted) | 4.17 Million | 8.22 Million | 8.25 Million | 8.31 Million | - | 4796.00 |
Gross Margin | - | 0.39 | - | - | 0.65 | 0.69 |
EBIT Margin | - | 0.27 | - | - | 0.97 | -0.28 |
Profit Margin | - | 0.18 | - | - | -2.64 | -1.60 |
EBITDA | - | 1.74 Million | -1000.00 | - | -1.29 Million | -1.05 Million |
Earnings Before Tax Margin | - | 0.23 | - | - | -1.10 | -1.01 |
Breakdown | 2023 Q3 | 2023 Q2 | 2023 Q1 | 2022 FY | 2022 Q3 | 2022 Q2 |
---|---|---|---|---|---|---|
Revenue | - | - | 1.07 Million | - | 1.42 Million | 1.43 Million |
Cost of Revenue | - | - | 516.12 Thousand | - | 440.23 Thousand | 979.65 Thousand |
Gross Profit | - | - | 558.38 Thousand | - | 980.44 Thousand | 454.93 Thousand |
Operating Expenses | - | - | 79.35 Thousand | - | 74.32 Thousand | 305.55 Thousand |
Selling, General and Administrative Expenses | - | - | 79.35 Thousand | - | 74.32 Thousand | 305.55 Thousand |
Research and Development Expenses | - | - | - | - | - | - |
Other Expenses | - | - | - | - | - | - |
Cost and Expenses | - | - | 595.47 Thousand | - | 514.55 Thousand | 1.28 Million |
Operating Income | - | - | 479.03 Thousand | - | 906.12 Thousand | 149.38 Thousand |
Interest Expense | - | - | 82.84 Thousand | - | - | 45.46 Thousand |
Income Tax Expense | - | - | 5.00 | - | -27.08 Thousand | 5.00 |
Earnings before Tax | - | - | 387 Thousand | - | 915.46 Thousand | 103.91 Thousand |
Net Income | - | - | 387 Thousand | - | 915.46 Thousand | 103.91 Thousand |
Earnings Per Share Basic | - | - | 0.09 | - | 0.22 | 0.03 |
Earnings Per Share Diluted | - | - | 0.09 | - | 0.22 | 0.02 |
Weighted Average Shares Outstanding | - | - | 4.13 Million | 4.17 Million | 4.13 Million | 4.13 Million |
Weighted Average Shares Outstanding (Diluted) | - | - | 4.17 Million | 4.17 Million | 4.17 Million | 4.17 Million |
Gross Margin | - | - | 0.52 | - | 0.69 | 0.32 |
EBIT Margin | - | - | 0.54 | - | 0.64 | 0.17 |
Profit Margin | - | - | 0.36 | - | 0.64 | 0.07 |
EBITDA | - | - | 579.97 Thousand | - | 906.12 Thousand | 250.32 Thousand |
Earnings Before Tax Margin | - | - | 0.45 | - | 0.64 | 0.10 |
SLSDF
CARCY
FESA3
DIABIO
GENPHARMA
GATE